Comorbidities of systemic lupus erythematosus prior to and following diagnosis in different age-at-onset groups. (July 2022)

• Record Type: Journal Article
• Authors: Yu, Cheng-Ya; Kuo, Chang-Fu; Chou, I-Jun; Chen, Jung-Sheng; Lu, Hung-Yi; Wu, Chao-Yi; Chen, Li-Chen; Huang, Jing-Long; Yeh, Kuo-Wei
• Is Part Of: Lupus. Volume 31:Number 8(2022)
• Page Start: 963
• Page End: 973
• Publication Date: 2022-07
• Subjects: Systemic lupus erythematosus -- comorbidity -- mortality -- child-onset -- late-onset -- herpes zoster infection; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/09612033221100908
• Languages: English
• ISSNs: 0961-2033

Abstract

Objectives: Systemic lupus erythematosus (SLE) is a female-dominated autoimmune disease that can occur at any age and has a diverse course. The clinical manifestation of this disease can vary depending on the patient's age at onset. The aim of this study was to characterise the comorbidities at the time of SLE diagnosis and after in different age groups. Methods: A total 1042 incident cases of SLE with a Catastrophic Illness Card in 2005 and 10, 420 age- and sex-matched controls from the general population registered in the National Health Insurance Research Database in Taiwan were enrolled in the study. The risk of comorbidities before (adjusted odds ratio, [aOR]) and after (adjusted hazard ratio, [aHR]) of SLE was analysed. The burden of these SLE-associated comorbidities was weight by the Charlson comorbidity index (CCI). We used the cumulative incidence to evaluate the impact of comorbidities on different age onset groups. Results: In this study, musculoskeletal diseases had the highest positive association (aOR, 5.29; 95% confidence interval [CI]: 4.25–6.57) prior to the diagnosis of SLE and they were also the most common developing incident comorbidity after the diagnosis (HR, 13.7; 95% CI: 11.91–15.77). It only took less than 1 year for 50% of the late-onset SLE patients to develop any increase in CCI score. The developing comorbidities attributed to 16.3% all-cause mortality and they had the greatest impact on late-onset SLE patients, with 33.3% cumulative incidence to all-cause mortality. There is no difference in the incidence of infectious diseases across different age groups. The herpes zoster infection had the greatest cumulative incidence among the category of infection diseases in child-onset SLE patients. Conclusion: SLE patients had increased risks of multiple pre-existing comorbidities at diagnosis. The developed comorbidity after diagnosis could contribute to all-cause mortality. The herpes zoster infection is primarily an issue in child-onset SLE patients.